BioSpace News Archive

ViaClean Technologies, a biotech company that develops, manufactures and markets environmentally responsible solutions that protect surfaces, today announced the appointment of Todd Gatzulis as Chief Operating Officer.

MedLever is pleased to announce the release of a new solution built on the MedLever Platform™ for workflow automation and interoperability.

According to Coherent Market Insights, the global digital microscopes market is estimated to be valued at US$ 1,124.0 million in 2020, and is expected to exhibit a CAGR of 6.5% during the forecast period (2020-2027).

Strategic Vaccines, LLC has signed a Memorandum of Understanding with the Texas A&M Center for Innovation in Advanced Development and Manufacturing to establish a FlowVax vaccine platform manufacturing center at Texas A&M’s College Station to rapidly respond to emerging viral threats.

Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug candidates for the treatment of aged related diseases, including neuromuscular diseases, today announces that the United States (US) Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application to proceed with its clinical development program COVA

Abivax SA (Euronext Paris: FR0012333284 – ABVX), a late stage clinical biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today that the first patient has been treated in its Phase 2b/3 study of ABX464 in COVID-19 patients at the University Hospital Center in Nice, France (CHU Nice).

The COVID-19 pandemic has accelerated the use of telehealth and shined a spotlight on the need for the health care community to focus on access to convenient devices to ensure the digital revolution does not leave gaps in care.

Protara Therapeutics, Inc., a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, announced the grants of inducement non-qualified stock options to purchase an aggregate of 3,700 shares of common stock to one new employee.

Clinically Meaningful Benefit Observed in Patients Receiving QINLOCK Following Progression on Placebo - - Data Featured at the ESMO World Congress on Gastrointestinal Cancer 2020 Virtual Meeting - WALTHAM, Mass.--( BUSINESS WIRE )-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of new data from an exploratory analysis of progression-free survival (PFS) and overall survival (OS) for patients who crossed over t

BD announced that it will conduct a live webcast of its third fiscal quarter 2020 earnings conference call on Thursday, August 6, 2020, at 8:00 a.m.